Lv31
244 积分 2021-02-07 加入
Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer
10小时前
已完结
Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer
10小时前
已关闭
Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer
23小时前
已完结
Managing the renal primary in metastatic clear-cell RCC in the IO-TKI era: a systemic-first, response-adapted strategy
2天前
求助中
Re: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
3天前
已完结
Re: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
3天前
已完结
BCG-unresponsive non-muscle-invasive bladder cancer
4天前
已关闭
Adjuvant Pembrolizumab in Patients with Clear Cell Renal Cell Carcinoma: From Eligibility to Individual Treatment Decision
4天前
求助中
Shared decision-making in the treatment of metastatic prostate cancer
5天前
已完结
Diagnostic Performance of Nectin-4-targeted [(68)Ga]Ga-DOTA-N188 PET/CT versus [(18)F]-FDG PET/CT for Staging of Locally Advanced and Metastatic Urothelial Carcinoma: A Prospective, Single-center, Phase 2 Feasibility Trial
6天前
已关闭